#HCG 🧵to provide key technical analysis insight & learning through one of popular stock HCG (valid for long term investors & traders)
Please note there are no GOD rules in technical analysis, but discipline makes a rule GOD for us when transactions go for a toss
Keep reading..
Let us focus on 2 things: 1. Why as an investor I start any chart reading with monthly chart for longer term direction
2. Why relative performance matters
1. Importance of monthly charts: peaceful investing without much churn in portfolio and daily tracking (this is one of the ways, not the only way or best way to take decisions).
a. Exit: If one would have simply plotted relative performance with respect to NIFTY, he would
have got out in early 2018 and avoided whole decline and underperformance for next 2 years
b. Entry: Further, in June 2020, would have taken entry based on outperformance to NIFTY and would have continued to outperform NIFTY
c. Average up: Whenever stocks relative performance came at par with NIFTY, it created a temporary bottom and next leg of run from there
2. Why relative performance matters:
NIFTY return itself has been respectable 12-14% over long term and if one can outperform this without much fuss and peace of mind with lesser churn, not a bad idea. Relative strength performance analysis helps to ideate the same
Currently, HCG has started underperforming NIFTY though not by a heavy margin but for last few months unless last few times when it rebounded quickly. No one will know the future but it is all about discipline of well tested rules which a protection cover to save from big falls
and ride big gains.
So, this was all about blending 2 concepts - relative strength and longer timeframes to simplify some of the concepts.
At Scientific Investing, we love to teach many such concepts and will be teaching in detail through our CMT level study sessions and much more in our practitioner membership. You can explore the same here. learn.scientificinvesting.in/learn/SI-PRACT…
Also, we love to teach about rule building, quantification, back testing, building systems and algorithms picking such ideas in our QUANTS learning track. You can explore it here. learn.scientificinvesting.in/learn/QUANTECH
Like and share if this was useful for wider reach🙏
Remember the key message - Its not about predicting a perfect buy or sell call or trying to predict HCG ka kya hoga. The key message is bigger and about patterns/rules/discipline and systems - focus there
Also, think more, conclude less - Killing all this analysis above - Why it looked so beautiful - because either the stock was in continuous uptrend or downtrend. The moment it goes no where for month doing criss cross, the rule may become pain in the ass which means it needs
more thoughts. Think about it. My goal is only to make you think and not talk about what will happen to HCG or what a great or crappy rule is this. There is nothing perfect but there are always better solutions n possibility for improvement
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Yesterday, I shared this data point of % of companies hitting 52 week low close to ILFS Oct 2018 number.
Question is what is the significance of this data?
Let us explore
The reason to share this data is much more interesting. In current market, people would say - do not catch falling knife, let it bottom etc.
What if you invested in all those days when more than 20% companies were making 52 week low?
Can you backtest return of all such scenarios since last 10-20 years?
Got reminded of my Face2Face video done 4 years back where I presented lot of backtested outputs including how your returns would pan out
Here is this data right from 2006. The red bars are % of companies making 52W low
Though some of these metric are gaining popularity now, we had done lot of exploratory analysis and backtesting around these metric 4-5 years back when I was conceptualizing Scientific Investing . You can watch the full video here:
For SMALLCAP 250, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
For NIFTY NEXT 50, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
For NIFTY 50, based on Q3FY25 results so far:
❓Best performing companies?
❓Attractively valued companies?
❓Both attractively valued and best performing?
🧵to answer all such questions to help to filter interesting ideas for research
1/15 🚀 Introducing Aarti Pharmalabs Ltd!
They make APIs, Xanthine Derivatives, and offer CDMO/CMO services for drug development and manufacturing.
Let’s break it down step by step! 🧵👇
2/15 🏢 Company Background:
● Originally part of Aarti Industries, Aarti Pharmalabs became a separate entity in 2022.
● Focus: Manufacturing key pharmaceutical ingredients, intermediates, and offering contract manufacturing for drug development.
● Their goal? To supply high-quality ingredients for medicines, energy drinks, and supplements globally.
3/15 🌿 What are APIs (Active Pharmaceutical Ingredients)?
● APIs are the active components in medicines that provide therapeutic effects.
○ Example: The ingredient in cancer, pain relief, and respiratory drugs.
● Intermediates are chemical compounds used to create APIs.
○ Think of intermediates as the building blocks of medicines
➡️ Aarti manufactures both!
RBI released Financial Stability Report - Dec 2024 (half yearly publication covering financial sector)
🧵 sharing key insights and visuals from the report covering macro, banking, investment and other regulatory aspects after going through the report
To start with market, how much the EPS needs to grow to justify the existing valuation against historic multiple.
Against this, Q2 growth was below 10% YoY
Do track our newsletters where we cover such things in detail on quarterly basis:
Subscribe to Newsletters: scientificinvesting.in